Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate

Biotech Targets Triple-Negative Breast Cancer and Lymphoma

The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.

Merck KGaA Darmstadt
Merck KGaA has licensed the drug to Diaccurate, but will maintain an active interest in the compound, and has taken a stakeholding in the biotech.

Merck KGaA has licensed to French biotech Diaccurate a PAM inhibitor candidate which could treat a broad range of tumors, including triple-negative breast cancer (TNBC) and relapsed/refractory B-cell and T-cell lymphomas.

For Merck KGaA, the deal frees up space in its cancer-dominated pipeline, and for Paris-based Diaccurate it adds a more...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip